Sight Sciences (SGHT) Revenue & Revenue Breakdown
Sight Sciences Revenue Highlights
Latest Revenue (Y)
$77.36M
Latest Revenue (Q)
$19.91M
Main Segment (Y)
Surgical Glaucoma
Sight Sciences Revenue by Period
Sight Sciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $77.36M | -3.13% |
| 2024-12-31 | $79.87M | -1.47% |
| 2023-12-31 | $81.06M | 13.63% |
| 2022-12-31 | $71.33M | 45.70% |
| 2021-12-31 | $48.96M | 77.12% |
| 2020-12-31 | $27.64M | 18.38% |
| 2019-12-31 | $23.35M | 210.07% |
| 2018-12-31 | $7.53M | - |
Sight Sciences generated $77.36M in revenue during NA 2025, up -3.13% compared to the previous quarter, and up 279.90% compared to the same period a year ago.
Sight Sciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $19.91M | 1.75% |
| 2025-06-30 | $19.56M | 11.74% |
| 2025-03-31 | $17.51M | -8.21% |
| 2024-12-31 | $19.07M | -5.37% |
| 2024-09-30 | $20.16M | -5.68% |
| 2024-06-30 | $21.37M | 10.93% |
| 2024-03-31 | $19.27M | 2.74% |
| 2023-12-31 | $18.75M | -6.29% |
| 2023-09-30 | $20.01M | -14.75% |
| 2023-06-30 | $23.47M | 24.69% |
| 2023-03-31 | $18.82M | -8.37% |
| 2022-12-31 | $20.54M | 9.99% |
| 2022-09-30 | $18.68M | 8.40% |
| 2022-06-30 | $17.23M | 15.78% |
| 2022-03-31 | $14.88M | 1.33% |
| 2021-12-31 | $14.69M | 12.09% |
| 2021-09-30 | $13.10M | 4.52% |
| 2021-06-30 | $12.54M | 45.17% |
| 2021-03-31 | $8.63M | -3.96% |
| 2020-12-31 | $8.99M | 3.93% |
| 2020-09-30 | $8.65M | 147.03% |
| 2020-06-30 | $3.50M | -46.09% |
| 2020-03-31 | $6.50M | - |
Sight Sciences generated $19.91M in revenue during Q3 2025, up 1.75% compared to the previous quarter, and up 93.15% compared to the same period a year ago.
Sight Sciences Revenue Breakdown
Sight Sciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Dry Eye | $1.64M | $3.96M | $6.75M | $5.74M | $2.46M |
| Surgical Glaucoma | $75.72M | $75.90M | $74.31M | $65.59M | $46.50M |
Latest
Sight Sciences's latest annual revenue breakdown by segment (product or service), as of Dec 25: Surgical Glaucoma (97.88%), and Dry Eye (2.12%).
Quarterly Revenue by Product
| Product/Service | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical Glaucoma | $19.66M | $19.72M | $19.23M | $17.11M | $18.77M | $18.63M | $20.24M | $18.26M | $17.15M | $18.43M | $21.40M | $17.33M | $18.75M | $17.07M | $15.90M | $13.87M | $13.92M | $12.45M | $11.99M |
| Dry Eye | $724.00K | $188.00K | $333.00K | $394.00K | $305.00K | $1.52M | $1.13M | $1.01M | $2.54M | $1.58M | $1.14M | $1.49M | $1.79M | $1.60M | $1.33M | $1.01M | $762.00K | $655.00K | $547.00K |
Latest
Sight Sciences's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Surgical Glaucoma (96.45%), and Dry Eye (3.55%).
Sight Sciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| OMI | Owens & Minor | $2.76B | $697.26M |
| VMD | Viemed Healthcare | $270.28M | $71.91M |
| CERS | Cerus | $206.13M | $52.70M |
| QTRX | Quanterix | $138.90M | $40.23M |
| LFCR | Lifecore Biomedical | $128.26M | $31.11M |
| SGHT | Sight Sciences | $77.36M | $19.91M |
| CVRX | CVRx | $56.65M | $14.69M |
| MASS | 908 Devices | $56.20M | $14.01M |
| SENS | Senseonics | $35.26M | $8.10M |
| SNWV | SANUWAVE Health | $32.63M | $11.45M |
| PRQR | ProQR Therapeutics | $6.38M | $4.48M |